Samba Participates in JP Morgan Healthcare... 7 Consecutive Years of Main Track Presentations

Offline Event Held After 2 Years
President John Lim Announces Directly on the 11th

In an online press conference held after the main track virtual presentation at the 39th 'JP Morgan Healthcare Conference' last January, John Rim, President of Samsung Biologics, is speaking. (Photo by Samsung Biologics)

[Asia Economy Reporter Chunhee Lee] Samsung Biologics announced on the 26th that it will participate in the 'JP Morgan Healthcare Conference' held in San Francisco, USA, from the 9th to the 12th of next month.

Marking its 41st year, the JP Morgan Healthcare Conference is the largest industry event where global bio and pharmaceutical companies and investors gather in one place. Due to the COVID-19 pandemic, it was held virtually from 2021 but will resume offline this year.

Samsung Biologics has once again received an official invitation from JP Morgan this year and plans to deliver a main track presentation for the seventh consecutive year since being the first Korean company invited to the Main Track in 2017.

John Rim, President of Samsung Biologics, will present on the 11th of next month at 2:15 PM in the Grand Ballroom, which is reserved exclusively for global major pharmaceutical companies within the Main Track. He will present the company's key achievements based on the three major growth pillars: production capacity, portfolio, and global geography, and will outline the business direction for next year as well as the mid-to-long-term vision.

A Samsung Biologics official stated, "As the event resumes face-to-face after three years, we plan to focus on actively engaging with clients and investors to promote Samsung Biologics' differentiated global Contract Development and Manufacturing Organization (CDMO) competitiveness and to expand partnerships."

This content was produced with the assistance of AI translation services.